Bayer Aktienges Ads (BAYRY) 149.0500 $BAYRY
Atrial Flutter - API Insights 2015-2016
M2 - Fri Jul 10, 9:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2zgp2x/atrial) has announced the addition of the "Atrial Flutter-API Insights" report to their offering. Atrial Flutter-API Insights, 2015 report provides Atrial Flutter drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Atrial Flutter. The Report provides the India and China API Manufactures who are driving the current API Market. The report also highlights the patent, patent exclusivity information and competitive landscape. The research analysis also presents the global sales forecasts data for the Atrial Flutter drugs till 2016. The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. Scope - A snapshot of the global Market therapeutics scenario for Attention Deficit Hyperactivity Disorder (ADHD). - A review of the marketed products under prescription for Attention Deficit Hyperactivity Disorder (ADHD), regulatory information and marketing status. - Coverage of global patent coverage and detailed commentaries on the US patent challenges. - Graphical representation of investigational products for patent expiry and market exclusivities across the globe. - Product profiles for marketed products for Attention Deficit Hyperactivity Disorder (ADHD) with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details. - Coverage of API Manufacturers for Attention Deficit Hyperactivity Disorder (ADHD) drugs in the United States, Europe and Asian Regions with location details. - Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Attention Deficit Hyperactivity Disorder (ADHD) drugs. - Key discontinued Marketed products. - Global Sales Figure from 2012-2016. Companies Mentioned - G. D. Searle, LLC - Pfizer Inc. - Wyeth Pharmaceuticals, Inc. - Baxter Healthcare Corporation - Eli Lilly and Company - Warner Chilcott Company, Inc. - Bayer AG - Abbott Laboratories - GlaxoSmithKline plc - Bioniche Pharma USA LLC. For more information visit http://www.researchandmarkets.com/research/2zgp2x/atrial
ABT: 49.93 (+0.74), PFE: 34.36 (+0.50), LLY: 88.29 (+0.81), GSK: 42.45 (+0.65)
Global Market Study on Animal Healthcare 2014-2019 - Feed Additives to Witness Highest Growth
M2 - Fri Jul 10, 7:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bmg2hr/global_market) has announced the addition of the "Global Market Study on Animal Healthcare: Feed Additives to Witness Highest Growth by 2019" report to their offering. Increasing population of companion and production animals is driving the global animal healthcare market. The animals that serve man by giving companionship and guarding their houses/offices are termed as companion animals, while those animals which serve mankind with their meat and milk and fur are called production animals. The new types of diseases in animals and their transfer to humans via their product consumption and companionship are escalating the animal healthcare market globally. However, some challenges in the form of regulations have emerged against the excess use of antibiotics in production animals, and legislations and protest of animal activists and institutions against animal research. The animal healthcare market is very competitive with the top ten players accounting for about three-fourth of the market. The companies are focusing on their research and development activities to produce better pharmaceutical and vaccine products for the existing and newly diagnosed diseases. The animal healthcare market is segmented as feed additives, pharmaceuticals and vaccines. Feed additives can be further categorized as nutritional feed additives and medicinal feed additives. Nutritional feed additives include amino acids, minerals and vitamins and are used for production animals for their optimal growth. Medicinal feed additives on the other hand include hormones, enzymes, immune-modulators, probiotics and prebiotics and feed acidifiers which target specific diseases in production and companion animals. Pharmaceutical products mainly comprise of endoparasiticides, ectoparasiticides, endectocides, antibiotics, anti-inflammatories and medicines for reproductive problems. Vaccines make animals disease-immune for a particular disease. Key Topics Covered: Chapter 1 Preface Chapter 2 Market Synopsis Chapter 3 Porter's Five Forces Analysis Chapter 4 Industry Overview Chapter 5 Market Size and Forecast by Product Chapter 6 Market Size and Forecast by Animal Type Chapter 7 Market Size and Forecast by Geography Chapter 8 Competitive Scenario Chapter 9 Company Profiles - Bayer AG - Boehringer Ingelheim GmbH - Ceva Sant? Animale - Elanco Products Company - MERIAL Limited - Merck & Co., Inc. - Novartis Animal Health Inc. - Vetoquinol SA - Virbac SA - Zoetis Inc. For more information visit http://www.researchandmarkets.com/research/bm...bal_market
ZTS: 46.96 (+0.39), MRK: 57.95 (+0.57), NVS: 103.22 (+3.20)
Global High-Grade Glioma Pipeline Report 2015 - 13 Companies & 22 Drug Profiles
M2 - Fri Jul 10, 3:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6kzhm8/highgrade_glioma) has announced the addition of the "High-Grade Glioma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for High-Grade Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High-Grade Glioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AngioChem Inc. - Bayer AG - Boehringer Ingelheim GmbH - Cavion LLC - GlaxoSmithKline plc - Kinex Pharmaceuticals, LLC - Millennium Pharmaceuticals, Inc. - Oncolytics Biotech Inc. - Sanofi - Stemline Therapeutics, Inc. - Targepeutics, Inc. - Tocagen Inc. - Virttu Biologics Limited Drug Profiles - (dabrafenib mesylate trametinib dimethyl sulfoxide) - alisertib - ANG-1005 - crenolanib besylate - Dendritic Cell Therapy for Gliomas - Dendritic Cell Therapy for Oncology - Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - GB-13 - Gene Therapy for High-Grade Glioma and Liver Transplantation - HSV-1716 - KX-02 - mibefradil dihydrochloride - nintedanib - pelareorep - plerixafor - SL-701 - sorafenib tosylate - Stem Cell Therapy for Glioma - TBX-01 - Toca-Gamma - Toca-RNAi - vocimagene amiretrorepvec flucytosine ER For more information visit http://www.researchandmarkets.com/research/6k...ade_glioma
ONCY: 0.58 (+0.03), GSK: 42.45 (+0.65), STML: 11.86 (+0.03)
Chronic Heart Failure Pipeline Report 2015 - 16 Companies & 26 Drug Profiles
M2 - Fri Jul 10, 3:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z3fzgp/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AnGes MG, Inc. - ARCA biopharma, Inc. - Bayer AG - Bial - Portela & Ca, S.A. - Celyad - Jiangsu Hengrui Medicine Co., Ltd. - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Mesoblast Limited - Novartis AG - Pfizer Inc. - PhaseBio Pharmaceuticals, Inc. - Sanofi - Stemedica Cell Technologies, Inc. - Zensun (Shanghai) Sci & Tech Co., Ltd. Drug Profiles - (sacubitril valsartan) - aliskiren fumarate - BAY-1067197 - beperminogene perplasmid - BIA-51058 - BR-5489 - C3BSCQR-1 - carvedilol phosphate ER - cenderitide - F-373280 - finerenone - furosemide - ivabradine - Mesenchymal Stem Cells - MPC-150IM - Neucardin - omecamtiv mecarbil - PB-1046 - Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - rivaroxaban - RNAi Gene Therapy to Inhibit STIM1 for Chronic Heart Failure and Atherosclerosis - SAR-296968 - serelaxin - sildenafil citrate - Small Molecule to Inhibit Beta-1 Adrenergic Receptor for Chronic Heart Failure - vericiguat For more information visit http://www.researchandmarkets.com/research/z3...onic_heart
PFE: 34.36 (+0.50), AMGN: 154.10 (+2.79), NVS: 103.22 (+3.20), CYAD: 52.42 (+3.19)
Regeneron and Sanofi Report Positive Data on Praluent - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 09, 10:30AM CDT
Regeneron Pharmaceuticals, Inc. (REGN) and its partner Sanofi (SNY) announced encouraging data from a phase III study on their PCSK9 antibody, Praluent.
AMGN: 154.10 (+2.79), SNY: 51.49 (+2.71), REGN: 526.01 (+16.98)
Chronic Kidney Disease (Chronic Renal Failure) Pipeline Review, H1 2015 - 28 Companies & 42 Drug Profiles
M2 - Thu Jul 09, 8:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/58mtw9/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - AFFiRiS AG - Angion Biomedica Corp. - Astellas Pharma Inc. - Bayer AG - Bio-inRen - Boryung Pharmaceutical Co., Ltd. - Celtic Biotech, Ltd. - Concert Pharmaceuticals, Inc. - Eli Lilly and Company - Evotec AG - Intercept Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Multi Gene Vascular Systems Ltd - Nippon Zoki Pharmaceutical Co., Ltd. - OPKO Health, Inc. - Otsuka Holdings Co., Ltd. - Prolong Pharmaceuticals - ProMetic Life Sciences Inc. - Quark Pharmaceuticals, Inc. - Reata Pharmaceuticals, Inc. - Red Glead Discovery AB - Resverlogix Corp. - Sphaera Pharma Pvt. Ltd. - Stelic Institute & Co. - Toray Industries, Inc. - VBS Pharmaceuticals - Vicore Pharma AB For more information visit http://www.researchandmarkets.com/research/58...nic_kidney
OPK: 16.55 (-0.01), ICPT: 247.71 (+4.45), LLY: 88.29 (+0.81), CNCE: 15.71 (+0.27), XLRN: 30.03 (+0.20)
Malignant Pleural Mesothelioma Pipeline Review, H1 2015 - 29 Companies & 36 Drug Profiles
M2 - Thu Jul 09, 6:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kfkk97/malignant_pleural) has announced the addition of the "Malignant Pleural Mesothelioma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Pleural Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Pleural Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Advantagene, Inc. - Amphera BV - Bayer AG - Biogen, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CanBas Co., Ltd. - Concordia Healthcare Corp. - EnGeneIC Ltd - F. Hoffmann-La Roche Ltd. - Five Prime Therapeutics, Inc. - Genelux Corporation - GlaxoSmithKline plc - Juno Therapeutics Inc. - MedImmune, LLC - Merck & Co., Inc. - MolMed S.p.A. - Morphotek, Inc. - Novartis AG - Oxford BioMedica plc - Pfizer Inc. - Pharma Mar, S.A. - Polaris Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Verastem, Inc. - Virttu Biologics Limited Drug Profiles - amatuximab - anetumab ravtansine - ascrinvacumab - BG-00001 - BMS-986148 - BNC-105 - CBP-501 - Cell Therapy 1 for Oncology - CRS-207 - defactinib hydrochloride - FP-1039 - ganetespib - Gene Therapy for Malignant Pleural Mesothelioma - Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma - GLONC-1 - GSK-2256098 - HSV-1716 - iCasp9M28z - JTCR-016 - MesoCancerVac - MesoCART - Monoclonal Antibody Conjugated to Target Mesothelin for Oncology - napabucasin - NGR-hTNF - nintedanib - pegargiminase - pembrolizumab - porfimer sodium - RG-7787 - Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Mestatic Lung Cancer - TargomiRs - trabectedin - tremelimumab - TroVax - Vaccine For Oncolytic Newcastle Disease Virus For more information visit http://www.researchandmarkets.com/research/kf...nt_pleural
ADRO: 30.58 (+0.28), PFE: 34.36 (+0.50), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), VSTM: 7.36 (+0.24), SNTA: 2.16 (-0.01), MRK: 57.95 (+0.57), JUNO: 52.05 (+1.72), CXRX: 73.69 (+1.67), FPRX: 26.01 (+0.37), NVS: 103.22 (+3.20)
Lung Adenocarcinoma Pipeline Review, H1 2015 - 19 Companies & 27 Drug Profiles
M2 - Thu Jul 09, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vrdth/lung) has announced the addition of the "Lung Adenocarcinoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Axelar AB - Bayer AG - BioNumerik Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - DiNonA Inc. - Eisai Co., Ltd. - Genentech, Inc. - Genmab A/S - Immunomedics, Inc. - Incyte Corporation - Medisyn Technologies, Inc. - Pfizer Inc. - Sanofi - VG Life Sciences, Inc. - Vichem Chemie Research Ltd. Drug Profiles - 4-B4 - afatinib - AV-203 - AXL-1717 - AZD-6738 - BAY-1163877 - Cell Therapy to Activate CD40L and GM-CSF for Metastatic Lung Adenocarcinoma - dacomitinib - DBPR-112 - dimesna - hydroxychloroquine sorafenib tosylate - Interferon Lambda-1 Linked Fab Dimer - lenvatinib - MAG-Tn3 - MT-477 - ruxolitinib phosphate - SAR-408701 - Small Molecule for Cancer - Small Molecule to Inhibit EGFR for Oncology - Small Molecules to Activate PKM2 for Lung Adenocarcinoma - Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma - SNX-5422 - solitomab - Stem Cell Therapy for Oncology - TdCyd - TF-011 Monomethyl Auristatin E - Vaccine for Lung Adenocarcinoma For more information visit http://www.researchandmarkets.com/research/3vrdth/lung
IMMU: 4.20 (+0.24), PFE: 34.36 (+0.50), INCY: 108.33 (+0.22), AZN: 66.45 (+1.90), AVEO: 1.57 (unch), AMGN: 154.10 (+2.79)
Renal Anemia Pipeline Review, H1 2015 - 24 Companies & 20 Drug Profiles
M2 - Thu Jul 09, 6:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rspq67/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3SBio Inc. - Acceleron Pharma, Inc. - Akebia Therapeutics, Inc. - Amgen Inc. - Aprogen, Inc. - Bayer AG - BIOCAD - CCM Duopharma Biotech Bhd. - Daiichi Sankyo Company, Limited - Dong-A Socio Group - FibroGen, Inc. - GlaxoSmithKline plc - Hospira, Inc. - Intas Pharmaceuticals Ltd. - Japan Tobacco Inc. - JCR Pharmaceuticals Co., Ltd. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Medgenics Inc. - Myungmoon pharmaceutical Co.,Ltd. - Panacea Biotec Limited - Pieris AG - ProMetic Life Sciences Inc. - Sandoz International GmbH - Zydus Cadila Healthcare Limited Drug Profiles - AKB-6548 - daprodustat - darbepoetin alfa (recombinant) - DS-1093 - EPO-018B - epoetin alfa (recombinant) - FG-2216 - FMX-8 - JTZ-951 - MDGN-201 - MM-P01-01 - molidustat - NuPIAO - PBI-1402 - PBI-4050 - PEG-EPO - PRS-080 - Recombinant Protein for Renal Anemia - roxadustat - sotatercept For more information visit http://www.researchandmarkets.com/research/rs...nal_anemia
MDGN: 6.47 (+0.37), AMGN: 154.10 (+2.79), GSK: 42.45 (+0.65), AKBA: 8.83 (+0.09), FGEN: 22.82 (+0.58), XLRN: 30.03 (+0.20)
Hemophilia B Pipeline Review, H1 2015 - 17 Companies & 24 Drug Profiles
M2 - Thu Jul 09, 6:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ndp4wj/hemophilia_b) has announced the addition of the "Hemophilia B - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hemophilia B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia B and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alnylam Pharmaceuticals, Inc. - Amarna Therapeutics B.V. - AstraZeneca PLC - Bayer AG - Biogen, Inc. - Catalyst Biosciences, Inc. - CSL Limited - Dimension Therapeutics, Inc. - Emergent BioSolutions Inc. - Novo Nordisk A/S - OPKO Health, Inc. - Pharming Group N.V. - rEVO Biologics - Sangamo BioSciences, Inc. - Spark Therapeutics, Inc. - The International Biotechnology Center (IBC) Generium - uniQure N.V. Drug Profiles - albutrepenonacog alfa - ALN-AT3 - AMT-060 - AZ-10047130 - BAX-335 - BAY-1093884 - CB-2679d - Cell Therapy for Hemophilia B - coagulation factor IX (recombinant) - coagulation factor VIIa (recombinant) - concizumab - CSL-689 - DTX-101 - Gene Therapy for Hemophilia B - Gene Therapy to Activate Factor IX for Hemophilia B - LR-769 - MOD-5014 - nonacog alfa biosimilar - nonacog beta pegol - PF-05280602 - Recombinant Enzyme to Replace Factor IX for Hemophilia B - SHP-624 - SPK-FIX - SVF-VIIa For more information visit http://www.researchandmarkets.com/research/nd...mophilia_b
NVO: 57.68 (+2.91), EBS: 33.85 (+1.10), OPK: 16.55 (-0.01), ONCE: 60.80 (+1.43), AZN: 66.45 (+1.90), SGMO: 9.86 (-0.02), RBIO: ()
Global Market Study on Botanical Supplements 2014-2020 - Personal Care Segment to Witness Highest Growth in the $90 Billion Market
M2 - Wed Jul 08, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mpw8qb/global_market) has announced the addition of the "Global Market Study on Botanical Supplements: Personal Care Segment to Witness Highest Growth by 2020" report to their offering. The global market for botanical supplements in value term grew from USD 45.1 billion in 2010 to USD 54.6 billion in 2013, and is expected to grow to USD 90.2 billion in 2020 growing at a CAGR of 7.5%. Also, Usage of botanical supplements by adult women (largest end user in 2013) is projected to increase to USD 32.9 billion in 2020 at a CAGR of 7.5%. Interest in healthy eating is influencing consumers to shift their dietary preferences in favour of food and food ingredients with potential health benefits. For consumers looking for a healthy lifestyle and seeking to reduce the risk of illness, herbal and botanical supplements (popularly known as herbal medicinal products) are among the best options. Botanical supplements include fresh or dried products in different forms, such as tablets, capsules, powders, and tea bags. Globally, garlic, ginger, santalum, plantago, ginseng, rhodiola extract, red clover extract, and soy extract are some of the most widely used botanical supplements. Increasing elderly population and little or no side effects of botanical supplements are expected to drive the global botanical supplements market. According to the Population Division of the United Nations Department of Economic and Social Affairs (UN-DESA), there were 841 million people aged 60 and above in 2013 compared to 205 million in 1950. The number is projected to reach over 2 billion by 2050. In the last few years, Europe has emerged as the largest market for botanical supplements, followed by Asia Pacific. In Asia Pacific, the long-standing tradition of using botanical medicine, the current economic development, and increasing urbanization are some factors driving the increasing demand for botanical supplements. Owing to these factors, Asia Pacific is expected to surpass Europe as the leading market for botanical supplements. The botanical supplements market is fragmented with several players operating at global or regional levels. The global botanical supplements market is highly fragmented, with top eight companies holding less than 40% market share. Ricola and Procter & Gamble are some of the major companies with global operations. Dabur operates mostly in India; however, the company started selling its products in the North American and European countries, such as the U.S., France, Germany and the U.K., recently. Key Topics Covered: Chapter 1 Preface Chapter 2 Market Synopsis Chapter 3 Porters Five Forces Analysis Chapter 4 Industry Overview Chapter 5 Market Size and Forecast, by Application Chapter 6 Market Size and Forecast, by End User Chapter 7 Market Size and Forecast, by Geography Chapter 8 Competitive Scenario Chapter 9 Company Profiles - BASF SE - Bayer AG - Bio-Botanica Inc. - Blackmores Limited - ChromaDex, Inc. - Integrated BioPharma, Inc. - NBTY, Inc. - NaturaLife Asia Co., Ltd. - Nutraceutical International Corporation - Pharmavite LLC - Procter & Gamble Company - Ricola AG - Surya Herbal, Ltd. - The Himalaya Drug Company For more information visit http://www.researchandmarkets.com/research/mp...bal_market
NUTR: 24.49 (+0.25), PG: 80.95 (+0.29)
Global Market Study on Diabetic Nephropathy 2014-2020
M2 - Wed Jul 08, 8:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jbq485/global_market) has announced the addition of the "Global Market Study on Diabetic Nephropathy: Asia to Witness Highest Growth by 2020" report to their offering. The global diabetic nephropathy market is estimated at USD 2,262.2 million in 2014. It is likely to grow at a CAGR of 5.6% from 2014 to 2020 to reach USD 3,145.9 million in 2020. Diabetic nephropathy is a disease of the kidney glomerulus and one of the most significant complications in terms of mortality and morbidity for patients with diabetes. Diabetic nephropathy is mainly characterized by macroalbuminuria. The presence of over 300 milligrams of albumin in the urine in 1 day is known as macroalbuminuria. Globally, the diabetic nephropathy market is witnessing significant growth due to rise in the incidence of diabetes and obesity in different regions of the world. In addition, increasing R&D investments in drug discovery and development by various companies, such as Sanofi, Eli Lilly and Mitsubishi Tanabe Pharma is also driving the growth of the market. However, stringent regulatory requirements and longer approval time for drugs as well as the lack of comprehensive therapeutic management for diabetic nephropathy are inhibiting the growth of diabetic nephropathy market. North America has the largest market for the global diabetic nephropathy market. However, In terms of growth, Asia is the fastest growing region. Disease Modifying Therapies (DMT) is the largest and fastest growing mode of treatment, whereas ACE inhibitors, is the largest and fastest growing DMT of diabetic nephropathy. North American market is estimated at USD 931.0 million in 2014 and is expected to reach USD 1,302.0 million in 2020, growing at a CAGR of 5.7% from 2014 to 2020. The global DMT market is estimated at USD 2,093.5 million in 2014 and is expected to reach USD 2,929.8 million in 2020, growing at a CAGR of 5.8% from 2014 to 2020. Companies Mentioned - AbbVie, Inc. - Abbott Laboratories - Bayer AG - Eli Lilly and Company - Merck & Co., Inc. - Mitsubishi Tanabe Pharma Corporation - Novartis AG - Pfizer, Inc. - Reata Pharmaceuticals, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/jb...bal_market
ABT: 49.93 (+0.74), PFE: 34.36 (+0.50), MRK: 57.95 (+0.57), LLY: 88.29 (+0.81), ABBV: 69.23 (+1.26), NVS: 103.22 (+3.20)
3 Reasons Value Stock Investors Will Love Bayer AG (BAYRY) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 08, 7:33AM CDT
Bayer AG looks great given its impressive metrics and estimate revisions
Global Market Study on Biosensor 2015: Asia-Pacific to Witness Highest Growth by 2020
M2 - Wed Jul 08, 5:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xdlmwl/global_market) has announced the addition of the "Global Market Study on Biosensor: Asia-Pacific to Witness Highest Growth by 2020" report to their offering. The global biosensors market is anticipated to grow from an estimated USD 12,963.6 million in 2014 to USD 22,551.2 million in 2020 at a CAGR of 9.7% during the forecast period. Globally, the biosensors market is witnessing significant growth due to increasing demand of point of care testing. In addition, rising prevalence of chronic and lifestyle associated diseases, growing geriatric population, increasing application of biosensors in various industries and growing application of nanotechnology in healthcare are also driving the growth of the market. In addition, emergence and demand of personalized medicine and non-invasive biosensors would also drive the growth for the market. However, strict regulatory requirements and reimbursement policy issues in healthcare system hamper growth of the global biosensors market. In addition, the regulatory process is not keeping pace with the rapid development of new medical technologies. North America is the largest market for global biosensors. Electrochemical biosensors are the most used technology of biosensors, medical diagnostics are the most popular application of biosensors and biosensors are mostly used in POCT. In terms of growth, Asia Pacific is the fastest growing region; optical biosensors make for the fastest growing type of technology, while security and bio-defense make for the fastest growing type of end user. The North American market is anticipated to grow from an estimated USD 5,693.4 million in 2014 to USD 9,522.2 million in 2020, growing at a CAGR of 8.9% during the forecast period. Key Topics Covered: Chapter 1 Preface Chapter 2 Market synopsis Chapter 3 Porter's five forces analysis Chapter 4 Industry overview Chapter 5 Global market size and forecast Chapter 6 Market size and forecast by technology Chapter 7 Market size and forecast by application Chapter 8 Market size and forecast by end user Chapter 9 Market size and forecast by geography Chapter 10 Competitive scenario Chapter 11 Company profiles - Abbott Laboratories, Inc. - Bayer AG - Hoffmann-La Roche, Ltd. - I-SENS, Inc. - Johnson & Johnson - LifeSensors, Inc. - Medtronic, Inc. - Nova Biomedical Corporation - Siemens Healthcare - TaiDoc Technology Corporation For more information visit http://www.researchandmarkets.com/research/xd...bal_market
JNJ: 99.53 (+1.13), ABT: 49.93 (+0.74), MDT: 74.37 (+1.28)
Global Mineral Supplements Market Study 2015 - Pharmaceutical to be the largest segment by 2020
M2 - Wed Jul 08, 5:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lnhtb4/global_market) has announced the addition of the "Global Market Study on Mineral Supplements: Pharmaceutical to be the largest segment by 2020" report to their offering. The global market for mineral supplements in value term grew from USD 7.3 million in 2010 to USD 8.9 million in 2013. Usage of mineral supplements in the pharmaceutical sector (largest application segment in 2013) is projected to increase to USD 6.9 million in 2020, at a CAGR of 7.1%. Also, Usage of mineral supplements by adult women (largest end user in 2013) is projected to increase from USD 3.4 million in 2014 at a CAGR of 7.5% during 2014-2020. The global supplements market is growing at a steady rate, majorly due to increasing consumer awareness about preventive healthcare. Mineral supplements are consumed in different forms, such as capsules, pills, powder, gel caps, granules, tablets, and liquid. Mineral supplements such as calcium, phosphorus, chromium, magnesium, sulfur, iron, zinc, folic acid, silicon, copper, and cobalt help consumers of different age groups to stay healthy and be free from nutrition deficiency diseases. Due to busy lifestyle, many working individuals are unable to follow a regular diet, leading to deficiency of nutrients, including minerals in the body. In order to address the need for nutrients and prevent mineral-deficiency diseases, individuals consume additional food supplements, including mineral supplements. With increasing awareness about daily nutritional requirements, more consumers are expected to start consuming mineral supplements in the coming years thus driving the mineral supplements market. Increasing age has adverse effects on the digestive organs, thus making it difficult in absorbing all the required nutrients from food. With growing age, people also tend to eat less due to loss of appetite. As a result, aging individuals do not get optimal amounts of minerals and other nutrients. Hence, they resort to additional supplements for proper nourishment. Among old age people, weakening of bones, poor eyesight, and poor digestive system are some of the common conditions. In order to remain fit and desired to live long, their dependency towards mineral supplements is growing. North America holds majority of the market for mineral supplements, followed by Asia Pacific and Europe. During forecasted period (2014-2020), mineral supplements market in Asia Pacific is expected to witness fastest growth rates owing to its increasing aging population and sustainable increase in disposable income. Key Topics Covered: Chapter 1 Preface Chapter 2 Market Synopsis Chapter 3 Porter's Five Forces Analysis Chapter 4 Market Overview Chapter 5 Market Size and Forecast by Application Chapter 6 Market Size and Forecast by End-Users Chapter 7 Market Size and Forecast by Geography Chapter 8 Competitive Scenario Chapter 9 Company Profiles - Amway - Atrium Innovations, Inc. - BASF SE (Badische Anilin- und Soda-Fabrik) - Bayer AG - E. I. du Pont de Nemours and Company - Glanbia Plc - Herbalife, Ltd. - Koninklijke DSM N.V. - NBTY, Inc. - Nu Skin Enterprises, Inc. For more information visit http://www.researchandmarkets.com/research/ln...bal_market
HLF: 51.41 (+1.17), NUS: 41.62 (-0.19)
Baxalta: A Spin-Off That Could Be Revalued Up To 50% Higher
Mike Serebrennik - at Seeking Alpha - Mon Jul 06, 4:30PM CDT
BIIB: 388.23 (-11.06), NVO: 57.68 (+2.91), BAX: 37.61 (+0.59), PFE: 34.36 (+0.50), BXLT: 30.85 (+0.79)
The Weekender
Aviate - at Seeking Alpha - Sun Jul 05, 3:57AM CDT
Greece and Europe It is not over-exaggerating to say that all eyes are on Greece this weekend as the Greek people vote in the referendum. Where it was once seen as the most unlikely of outcomes, there now seems to be a real risk of Grexit,...
GREK: 11.26 (+0.95), TI: 13.19 (+0.48), RYAAY: 73.25 (+1.50), APOL: 14.01 (+0.43), BUD: 126.61 (+6.21), EU: 20.54 (-0.08), VOD: 36.46 (+1.07), PSO: 19.11 (+0.56)
What Is Beyond Vision-Loss Blockbuster For Regeneron?
at Investor's Business Daily - Wed Jul 01, 3:12PM CDT
As people get older, they are more prone to vision loss from age-related macular degeneration. The severe "wet" version of the condition is the leading cause of blindness in the U.S., afflicting millions of people over 55. It's caused by leaky,...
GILD: 113.74 (+0.38), AMGN: 154.10 (+2.79), SNY: 51.49 (+2.71), REGN: 526.01 (+16.98), CELG: 118.84 (+1.97)
Bayer Files Hemophilia A Drug Marketing Application in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 01, 2:50PM CDT
The HealthCare segment at Bayer (BAYRY) announced that the company has submitted a Marketing Authorization Application in Japan for BAY 81-8973.
BIIB: 388.23 (-11.06), EBS: 33.85 (+1.10), ACOR: 34.07 (+0.65)
Premarket Biotech Digest: Geron's Sharp Gain, Bayer Essure AEs, Juno Moves Higher
Kanak Kanti De - at Seeking Alpha - Wed Jul 01, 6:18AM CDT
JNJ: 99.53 (+1.13), GILD: 113.74 (+0.38), GERN: 4.22 (+0.13), ABBV: 69.23 (+1.26), CELG: 118.84 (+1.97)
Atrial Flutter - API Insights 2015-2016
M2 - Fri Jul 10, 9:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2zgp2x/atrial) has announced the addition of the "Atrial Flutter-API Insights" report to their offering. Atrial Flutter-API Insights, 2015 report provides Atrial Flutter drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Atrial Flutter. The Report provides the India and China API Manufactures who are driving the current API Market. The report also highlights the patent, patent exclusivity information and competitive landscape. The research analysis also presents the global sales forecasts data for the Atrial Flutter drugs till 2016. The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. Scope - A snapshot of the global Market therapeutics scenario for Attention Deficit Hyperactivity Disorder (ADHD). - A review of the marketed products under prescription for Attention Deficit Hyperactivity Disorder (ADHD), regulatory information and marketing status. - Coverage of global patent coverage and detailed commentaries on the US patent challenges. - Graphical representation of investigational products for patent expiry and market exclusivities across the globe. - Product profiles for marketed products for Attention Deficit Hyperactivity Disorder (ADHD) with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details. - Coverage of API Manufacturers for Attention Deficit Hyperactivity Disorder (ADHD) drugs in the United States, Europe and Asian Regions with location details. - Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Attention Deficit Hyperactivity Disorder (ADHD) drugs. - Key discontinued Marketed products. - Global Sales Figure from 2012-2016. Companies Mentioned - G. D. Searle, LLC - Pfizer Inc. - Wyeth Pharmaceuticals, Inc. - Baxter Healthcare Corporation - Eli Lilly and Company - Warner Chilcott Company, Inc. - Bayer AG - Abbott Laboratories - GlaxoSmithKline plc - Bioniche Pharma USA LLC. For more information visit http://www.researchandmarkets.com/research/2zgp2x/atrial
ABT: 49.93 (+0.74), PFE: 34.36 (+0.50), LLY: 88.29 (+0.81), GSK: 42.45 (+0.65)
Global Market Study on Animal Healthcare 2014-2019 - Feed Additives to Witness Highest Growth
M2 - Fri Jul 10, 7:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bmg2hr/global_market) has announced the addition of the "Global Market Study on Animal Healthcare: Feed Additives to Witness Highest Growth by 2019" report to their offering. Increasing population of companion and production animals is driving the global animal healthcare market. The animals that serve man by giving companionship and guarding their houses/offices are termed as companion animals, while those animals which serve mankind with their meat and milk and fur are called production animals. The new types of diseases in animals and their transfer to humans via their product consumption and companionship are escalating the animal healthcare market globally. However, some challenges in the form of regulations have emerged against the excess use of antibiotics in production animals, and legislations and protest of animal activists and institutions against animal research. The animal healthcare market is very competitive with the top ten players accounting for about three-fourth of the market. The companies are focusing on their research and development activities to produce better pharmaceutical and vaccine products for the existing and newly diagnosed diseases. The animal healthcare market is segmented as feed additives, pharmaceuticals and vaccines. Feed additives can be further categorized as nutritional feed additives and medicinal feed additives. Nutritional feed additives include amino acids, minerals and vitamins and are used for production animals for their optimal growth. Medicinal feed additives on the other hand include hormones, enzymes, immune-modulators, probiotics and prebiotics and feed acidifiers which target specific diseases in production and companion animals. Pharmaceutical products mainly comprise of endoparasiticides, ectoparasiticides, endectocides, antibiotics, anti-inflammatories and medicines for reproductive problems. Vaccines make animals disease-immune for a particular disease. Key Topics Covered: Chapter 1 Preface Chapter 2 Market Synopsis Chapter 3 Porter's Five Forces Analysis Chapter 4 Industry Overview Chapter 5 Market Size and Forecast by Product Chapter 6 Market Size and Forecast by Animal Type Chapter 7 Market Size and Forecast by Geography Chapter 8 Competitive Scenario Chapter 9 Company Profiles - Bayer AG - Boehringer Ingelheim GmbH - Ceva Sant? Animale - Elanco Products Company - MERIAL Limited - Merck & Co., Inc. - Novartis Animal Health Inc. - Vetoquinol SA - Virbac SA - Zoetis Inc. For more information visit http://www.researchandmarkets.com/research/bm...bal_market
ZTS: 46.96 (+0.39), MRK: 57.95 (+0.57), NVS: 103.22 (+3.20)
Global High-Grade Glioma Pipeline Report 2015 - 13 Companies & 22 Drug Profiles
M2 - Fri Jul 10, 3:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6kzhm8/highgrade_glioma) has announced the addition of the "High-Grade Glioma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for High-Grade Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High-Grade Glioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AngioChem Inc. - Bayer AG - Boehringer Ingelheim GmbH - Cavion LLC - GlaxoSmithKline plc - Kinex Pharmaceuticals, LLC - Millennium Pharmaceuticals, Inc. - Oncolytics Biotech Inc. - Sanofi - Stemline Therapeutics, Inc. - Targepeutics, Inc. - Tocagen Inc. - Virttu Biologics Limited Drug Profiles - (dabrafenib mesylate trametinib dimethyl sulfoxide) - alisertib - ANG-1005 - crenolanib besylate - Dendritic Cell Therapy for Gliomas - Dendritic Cell Therapy for Oncology - Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - GB-13 - Gene Therapy for High-Grade Glioma and Liver Transplantation - HSV-1716 - KX-02 - mibefradil dihydrochloride - nintedanib - pelareorep - plerixafor - SL-701 - sorafenib tosylate - Stem Cell Therapy for Glioma - TBX-01 - Toca-Gamma - Toca-RNAi - vocimagene amiretrorepvec flucytosine ER For more information visit http://www.researchandmarkets.com/research/6k...ade_glioma
ONCY: 0.58 (+0.03), GSK: 42.45 (+0.65), STML: 11.86 (+0.03)
Chronic Heart Failure Pipeline Report 2015 - 16 Companies & 26 Drug Profiles
M2 - Fri Jul 10, 3:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z3fzgp/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AnGes MG, Inc. - ARCA biopharma, Inc. - Bayer AG - Bial - Portela & Ca, S.A. - Celyad - Jiangsu Hengrui Medicine Co., Ltd. - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Mesoblast Limited - Novartis AG - Pfizer Inc. - PhaseBio Pharmaceuticals, Inc. - Sanofi - Stemedica Cell Technologies, Inc. - Zensun (Shanghai) Sci & Tech Co., Ltd. Drug Profiles - (sacubitril valsartan) - aliskiren fumarate - BAY-1067197 - beperminogene perplasmid - BIA-51058 - BR-5489 - C3BSCQR-1 - carvedilol phosphate ER - cenderitide - F-373280 - finerenone - furosemide - ivabradine - Mesenchymal Stem Cells - MPC-150IM - Neucardin - omecamtiv mecarbil - PB-1046 - Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - rivaroxaban - RNAi Gene Therapy to Inhibit STIM1 for Chronic Heart Failure and Atherosclerosis - SAR-296968 - serelaxin - sildenafil citrate - Small Molecule to Inhibit Beta-1 Adrenergic Receptor for Chronic Heart Failure - vericiguat For more information visit http://www.researchandmarkets.com/research/z3...onic_heart
PFE: 34.36 (+0.50), AMGN: 154.10 (+2.79), NVS: 103.22 (+3.20), CYAD: 52.42 (+3.19)
Regeneron and Sanofi Report Positive Data on Praluent - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 09, 10:30AM CDT
Regeneron Pharmaceuticals, Inc. (REGN) and its partner Sanofi (SNY) announced encouraging data from a phase III study on their PCSK9 antibody, Praluent.
AMGN: 154.10 (+2.79), SNY: 51.49 (+2.71), REGN: 526.01 (+16.98)
Chronic Kidney Disease (Chronic Renal Failure) Pipeline Review, H1 2015 - 28 Companies & 42 Drug Profiles
M2 - Thu Jul 09, 8:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/58mtw9/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - AFFiRiS AG - Angion Biomedica Corp. - Astellas Pharma Inc. - Bayer AG - Bio-inRen - Boryung Pharmaceutical Co., Ltd. - Celtic Biotech, Ltd. - Concert Pharmaceuticals, Inc. - Eli Lilly and Company - Evotec AG - Intercept Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Multi Gene Vascular Systems Ltd - Nippon Zoki Pharmaceutical Co., Ltd. - OPKO Health, Inc. - Otsuka Holdings Co., Ltd. - Prolong Pharmaceuticals - ProMetic Life Sciences Inc. - Quark Pharmaceuticals, Inc. - Reata Pharmaceuticals, Inc. - Red Glead Discovery AB - Resverlogix Corp. - Sphaera Pharma Pvt. Ltd. - Stelic Institute & Co. - Toray Industries, Inc. - VBS Pharmaceuticals - Vicore Pharma AB For more information visit http://www.researchandmarkets.com/research/58...nic_kidney
OPK: 16.55 (-0.01), ICPT: 247.71 (+4.45), LLY: 88.29 (+0.81), CNCE: 15.71 (+0.27), XLRN: 30.03 (+0.20)
Malignant Pleural Mesothelioma Pipeline Review, H1 2015 - 29 Companies & 36 Drug Profiles
M2 - Thu Jul 09, 6:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kfkk97/malignant_pleural) has announced the addition of the "Malignant Pleural Mesothelioma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Pleural Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Pleural Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Advantagene, Inc. - Amphera BV - Bayer AG - Biogen, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CanBas Co., Ltd. - Concordia Healthcare Corp. - EnGeneIC Ltd - F. Hoffmann-La Roche Ltd. - Five Prime Therapeutics, Inc. - Genelux Corporation - GlaxoSmithKline plc - Juno Therapeutics Inc. - MedImmune, LLC - Merck & Co., Inc. - MolMed S.p.A. - Morphotek, Inc. - Novartis AG - Oxford BioMedica plc - Pfizer Inc. - Pharma Mar, S.A. - Polaris Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Verastem, Inc. - Virttu Biologics Limited Drug Profiles - amatuximab - anetumab ravtansine - ascrinvacumab - BG-00001 - BMS-986148 - BNC-105 - CBP-501 - Cell Therapy 1 for Oncology - CRS-207 - defactinib hydrochloride - FP-1039 - ganetespib - Gene Therapy for Malignant Pleural Mesothelioma - Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma - GLONC-1 - GSK-2256098 - HSV-1716 - iCasp9M28z - JTCR-016 - MesoCancerVac - MesoCART - Monoclonal Antibody Conjugated to Target Mesothelin for Oncology - napabucasin - NGR-hTNF - nintedanib - pegargiminase - pembrolizumab - porfimer sodium - RG-7787 - Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Mestatic Lung Cancer - TargomiRs - trabectedin - tremelimumab - TroVax - Vaccine For Oncolytic Newcastle Disease Virus For more information visit http://www.researchandmarkets.com/research/kf...nt_pleural
ADRO: 30.58 (+0.28), PFE: 34.36 (+0.50), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), VSTM: 7.36 (+0.24), SNTA: 2.16 (-0.01), MRK: 57.95 (+0.57), JUNO: 52.05 (+1.72), CXRX: 73.69 (+1.67), FPRX: 26.01 (+0.37), NVS: 103.22 (+3.20)
Lung Adenocarcinoma Pipeline Review, H1 2015 - 19 Companies & 27 Drug Profiles
M2 - Thu Jul 09, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vrdth/lung) has announced the addition of the "Lung Adenocarcinoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Axelar AB - Bayer AG - BioNumerik Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - DiNonA Inc. - Eisai Co., Ltd. - Genentech, Inc. - Genmab A/S - Immunomedics, Inc. - Incyte Corporation - Medisyn Technologies, Inc. - Pfizer Inc. - Sanofi - VG Life Sciences, Inc. - Vichem Chemie Research Ltd. Drug Profiles - 4-B4 - afatinib - AV-203 - AXL-1717 - AZD-6738 - BAY-1163877 - Cell Therapy to Activate CD40L and GM-CSF for Metastatic Lung Adenocarcinoma - dacomitinib - DBPR-112 - dimesna - hydroxychloroquine sorafenib tosylate - Interferon Lambda-1 Linked Fab Dimer - lenvatinib - MAG-Tn3 - MT-477 - ruxolitinib phosphate - SAR-408701 - Small Molecule for Cancer - Small Molecule to Inhibit EGFR for Oncology - Small Molecules to Activate PKM2 for Lung Adenocarcinoma - Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma - SNX-5422 - solitomab - Stem Cell Therapy for Oncology - TdCyd - TF-011 Monomethyl Auristatin E - Vaccine for Lung Adenocarcinoma For more information visit http://www.researchandmarkets.com/research/3vrdth/lung
IMMU: 4.20 (+0.24), PFE: 34.36 (+0.50), INCY: 108.33 (+0.22), AZN: 66.45 (+1.90), AVEO: 1.57 (unch), AMGN: 154.10 (+2.79)
Renal Anemia Pipeline Review, H1 2015 - 24 Companies & 20 Drug Profiles
M2 - Thu Jul 09, 6:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rspq67/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3SBio Inc. - Acceleron Pharma, Inc. - Akebia Therapeutics, Inc. - Amgen Inc. - Aprogen, Inc. - Bayer AG - BIOCAD - CCM Duopharma Biotech Bhd. - Daiichi Sankyo Company, Limited - Dong-A Socio Group - FibroGen, Inc. - GlaxoSmithKline plc - Hospira, Inc. - Intas Pharmaceuticals Ltd. - Japan Tobacco Inc. - JCR Pharmaceuticals Co., Ltd. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Medgenics Inc. - Myungmoon pharmaceutical Co.,Ltd. - Panacea Biotec Limited - Pieris AG - ProMetic Life Sciences Inc. - Sandoz International GmbH - Zydus Cadila Healthcare Limited Drug Profiles - AKB-6548 - daprodustat - darbepoetin alfa (recombinant) - DS-1093 - EPO-018B - epoetin alfa (recombinant) - FG-2216 - FMX-8 - JTZ-951 - MDGN-201 - MM-P01-01 - molidustat - NuPIAO - PBI-1402 - PBI-4050 - PEG-EPO - PRS-080 - Recombinant Protein for Renal Anemia - roxadustat - sotatercept For more information visit http://www.researchandmarkets.com/research/rs...nal_anemia
MDGN: 6.47 (+0.37), AMGN: 154.10 (+2.79), GSK: 42.45 (+0.65), AKBA: 8.83 (+0.09), FGEN: 22.82 (+0.58), XLRN: 30.03 (+0.20)
Hemophilia B Pipeline Review, H1 2015 - 17 Companies & 24 Drug Profiles
M2 - Thu Jul 09, 6:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ndp4wj/hemophilia_b) has announced the addition of the "Hemophilia B - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hemophilia B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia B and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alnylam Pharmaceuticals, Inc. - Amarna Therapeutics B.V. - AstraZeneca PLC - Bayer AG - Biogen, Inc. - Catalyst Biosciences, Inc. - CSL Limited - Dimension Therapeutics, Inc. - Emergent BioSolutions Inc. - Novo Nordisk A/S - OPKO Health, Inc. - Pharming Group N.V. - rEVO Biologics - Sangamo BioSciences, Inc. - Spark Therapeutics, Inc. - The International Biotechnology Center (IBC) Generium - uniQure N.V. Drug Profiles - albutrepenonacog alfa - ALN-AT3 - AMT-060 - AZ-10047130 - BAX-335 - BAY-1093884 - CB-2679d - Cell Therapy for Hemophilia B - coagulation factor IX (recombinant) - coagulation factor VIIa (recombinant) - concizumab - CSL-689 - DTX-101 - Gene Therapy for Hemophilia B - Gene Therapy to Activate Factor IX for Hemophilia B - LR-769 - MOD-5014 - nonacog alfa biosimilar - nonacog beta pegol - PF-05280602 - Recombinant Enzyme to Replace Factor IX for Hemophilia B - SHP-624 - SPK-FIX - SVF-VIIa For more information visit http://www.researchandmarkets.com/research/nd...mophilia_b
NVO: 57.68 (+2.91), EBS: 33.85 (+1.10), OPK: 16.55 (-0.01), ONCE: 60.80 (+1.43), AZN: 66.45 (+1.90), SGMO: 9.86 (-0.02), RBIO: ()
Global Market Study on Botanical Supplements 2014-2020 - Personal Care Segment to Witness Highest Growth in the $90 Billion Market
M2 - Wed Jul 08, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mpw8qb/global_market) has announced the addition of the "Global Market Study on Botanical Supplements: Personal Care Segment to Witness Highest Growth by 2020" report to their offering. The global market for botanical supplements in value term grew from USD 45.1 billion in 2010 to USD 54.6 billion in 2013, and is expected to grow to USD 90.2 billion in 2020 growing at a CAGR of 7.5%. Also, Usage of botanical supplements by adult women (largest end user in 2013) is projected to increase to USD 32.9 billion in 2020 at a CAGR of 7.5%. Interest in healthy eating is influencing consumers to shift their dietary preferences in favour of food and food ingredients with potential health benefits. For consumers looking for a healthy lifestyle and seeking to reduce the risk of illness, herbal and botanical supplements (popularly known as herbal medicinal products) are among the best options. Botanical supplements include fresh or dried products in different forms, such as tablets, capsules, powders, and tea bags. Globally, garlic, ginger, santalum, plantago, ginseng, rhodiola extract, red clover extract, and soy extract are some of the most widely used botanical supplements. Increasing elderly population and little or no side effects of botanical supplements are expected to drive the global botanical supplements market. According to the Population Division of the United Nations Department of Economic and Social Affairs (UN-DESA), there were 841 million people aged 60 and above in 2013 compared to 205 million in 1950. The number is projected to reach over 2 billion by 2050. In the last few years, Europe has emerged as the largest market for botanical supplements, followed by Asia Pacific. In Asia Pacific, the long-standing tradition of using botanical medicine, the current economic development, and increasing urbanization are some factors driving the increasing demand for botanical supplements. Owing to these factors, Asia Pacific is expected to surpass Europe as the leading market for botanical supplements. The botanical supplements market is fragmented with several players operating at global or regional levels. The global botanical supplements market is highly fragmented, with top eight companies holding less than 40% market share. Ricola and Procter & Gamble are some of the major companies with global operations. Dabur operates mostly in India; however, the company started selling its products in the North American and European countries, such as the U.S., France, Germany and the U.K., recently. Key Topics Covered: Chapter 1 Preface Chapter 2 Market Synopsis Chapter 3 Porters Five Forces Analysis Chapter 4 Industry Overview Chapter 5 Market Size and Forecast, by Application Chapter 6 Market Size and Forecast, by End User Chapter 7 Market Size and Forecast, by Geography Chapter 8 Competitive Scenario Chapter 9 Company Profiles - BASF SE - Bayer AG - Bio-Botanica Inc. - Blackmores Limited - ChromaDex, Inc. - Integrated BioPharma, Inc. - NBTY, Inc. - NaturaLife Asia Co., Ltd. - Nutraceutical International Corporation - Pharmavite LLC - Procter & Gamble Company - Ricola AG - Surya Herbal, Ltd. - The Himalaya Drug Company For more information visit http://www.researchandmarkets.com/research/mp...bal_market
NUTR: 24.49 (+0.25), PG: 80.95 (+0.29)
Global Market Study on Diabetic Nephropathy 2014-2020
M2 - Wed Jul 08, 8:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jbq485/global_market) has announced the addition of the "Global Market Study on Diabetic Nephropathy: Asia to Witness Highest Growth by 2020" report to their offering. The global diabetic nephropathy market is estimated at USD 2,262.2 million in 2014. It is likely to grow at a CAGR of 5.6% from 2014 to 2020 to reach USD 3,145.9 million in 2020. Diabetic nephropathy is a disease of the kidney glomerulus and one of the most significant complications in terms of mortality and morbidity for patients with diabetes. Diabetic nephropathy is mainly characterized by macroalbuminuria. The presence of over 300 milligrams of albumin in the urine in 1 day is known as macroalbuminuria. Globally, the diabetic nephropathy market is witnessing significant growth due to rise in the incidence of diabetes and obesity in different regions of the world. In addition, increasing R&D investments in drug discovery and development by various companies, such as Sanofi, Eli Lilly and Mitsubishi Tanabe Pharma is also driving the growth of the market. However, stringent regulatory requirements and longer approval time for drugs as well as the lack of comprehensive therapeutic management for diabetic nephropathy are inhibiting the growth of diabetic nephropathy market. North America has the largest market for the global diabetic nephropathy market. However, In terms of growth, Asia is the fastest growing region. Disease Modifying Therapies (DMT) is the largest and fastest growing mode of treatment, whereas ACE inhibitors, is the largest and fastest growing DMT of diabetic nephropathy. North American market is estimated at USD 931.0 million in 2014 and is expected to reach USD 1,302.0 million in 2020, growing at a CAGR of 5.7% from 2014 to 2020. The global DMT market is estimated at USD 2,093.5 million in 2014 and is expected to reach USD 2,929.8 million in 2020, growing at a CAGR of 5.8% from 2014 to 2020. Companies Mentioned - AbbVie, Inc. - Abbott Laboratories - Bayer AG - Eli Lilly and Company - Merck & Co., Inc. - Mitsubishi Tanabe Pharma Corporation - Novartis AG - Pfizer, Inc. - Reata Pharmaceuticals, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/jb...bal_market
ABT: 49.93 (+0.74), PFE: 34.36 (+0.50), MRK: 57.95 (+0.57), LLY: 88.29 (+0.81), ABBV: 69.23 (+1.26), NVS: 103.22 (+3.20)
3 Reasons Value Stock Investors Will Love Bayer AG (BAYRY) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 08, 7:33AM CDT
Bayer AG looks great given its impressive metrics and estimate revisions
Global Market Study on Biosensor 2015: Asia-Pacific to Witness Highest Growth by 2020
M2 - Wed Jul 08, 5:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xdlmwl/global_market) has announced the addition of the "Global Market Study on Biosensor: Asia-Pacific to Witness Highest Growth by 2020" report to their offering. The global biosensors market is anticipated to grow from an estimated USD 12,963.6 million in 2014 to USD 22,551.2 million in 2020 at a CAGR of 9.7% during the forecast period. Globally, the biosensors market is witnessing significant growth due to increasing demand of point of care testing. In addition, rising prevalence of chronic and lifestyle associated diseases, growing geriatric population, increasing application of biosensors in various industries and growing application of nanotechnology in healthcare are also driving the growth of the market. In addition, emergence and demand of personalized medicine and non-invasive biosensors would also drive the growth for the market. However, strict regulatory requirements and reimbursement policy issues in healthcare system hamper growth of the global biosensors market. In addition, the regulatory process is not keeping pace with the rapid development of new medical technologies. North America is the largest market for global biosensors. Electrochemical biosensors are the most used technology of biosensors, medical diagnostics are the most popular application of biosensors and biosensors are mostly used in POCT. In terms of growth, Asia Pacific is the fastest growing region; optical biosensors make for the fastest growing type of technology, while security and bio-defense make for the fastest growing type of end user. The North American market is anticipated to grow from an estimated USD 5,693.4 million in 2014 to USD 9,522.2 million in 2020, growing at a CAGR of 8.9% during the forecast period. Key Topics Covered: Chapter 1 Preface Chapter 2 Market synopsis Chapter 3 Porter's five forces analysis Chapter 4 Industry overview Chapter 5 Global market size and forecast Chapter 6 Market size and forecast by technology Chapter 7 Market size and forecast by application Chapter 8 Market size and forecast by end user Chapter 9 Market size and forecast by geography Chapter 10 Competitive scenario Chapter 11 Company profiles - Abbott Laboratories, Inc. - Bayer AG - Hoffmann-La Roche, Ltd. - I-SENS, Inc. - Johnson & Johnson - LifeSensors, Inc. - Medtronic, Inc. - Nova Biomedical Corporation - Siemens Healthcare - TaiDoc Technology Corporation For more information visit http://www.researchandmarkets.com/research/xd...bal_market
JNJ: 99.53 (+1.13), ABT: 49.93 (+0.74), MDT: 74.37 (+1.28)
Global Mineral Supplements Market Study 2015 - Pharmaceutical to be the largest segment by 2020
M2 - Wed Jul 08, 5:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lnhtb4/global_market) has announced the addition of the "Global Market Study on Mineral Supplements: Pharmaceutical to be the largest segment by 2020" report to their offering. The global market for mineral supplements in value term grew from USD 7.3 million in 2010 to USD 8.9 million in 2013. Usage of mineral supplements in the pharmaceutical sector (largest application segment in 2013) is projected to increase to USD 6.9 million in 2020, at a CAGR of 7.1%. Also, Usage of mineral supplements by adult women (largest end user in 2013) is projected to increase from USD 3.4 million in 2014 at a CAGR of 7.5% during 2014-2020. The global supplements market is growing at a steady rate, majorly due to increasing consumer awareness about preventive healthcare. Mineral supplements are consumed in different forms, such as capsules, pills, powder, gel caps, granules, tablets, and liquid. Mineral supplements such as calcium, phosphorus, chromium, magnesium, sulfur, iron, zinc, folic acid, silicon, copper, and cobalt help consumers of different age groups to stay healthy and be free from nutrition deficiency diseases. Due to busy lifestyle, many working individuals are unable to follow a regular diet, leading to deficiency of nutrients, including minerals in the body. In order to address the need for nutrients and prevent mineral-deficiency diseases, individuals consume additional food supplements, including mineral supplements. With increasing awareness about daily nutritional requirements, more consumers are expected to start consuming mineral supplements in the coming years thus driving the mineral supplements market. Increasing age has adverse effects on the digestive organs, thus making it difficult in absorbing all the required nutrients from food. With growing age, people also tend to eat less due to loss of appetite. As a result, aging individuals do not get optimal amounts of minerals and other nutrients. Hence, they resort to additional supplements for proper nourishment. Among old age people, weakening of bones, poor eyesight, and poor digestive system are some of the common conditions. In order to remain fit and desired to live long, their dependency towards mineral supplements is growing. North America holds majority of the market for mineral supplements, followed by Asia Pacific and Europe. During forecasted period (2014-2020), mineral supplements market in Asia Pacific is expected to witness fastest growth rates owing to its increasing aging population and sustainable increase in disposable income. Key Topics Covered: Chapter 1 Preface Chapter 2 Market Synopsis Chapter 3 Porter's Five Forces Analysis Chapter 4 Market Overview Chapter 5 Market Size and Forecast by Application Chapter 6 Market Size and Forecast by End-Users Chapter 7 Market Size and Forecast by Geography Chapter 8 Competitive Scenario Chapter 9 Company Profiles - Amway - Atrium Innovations, Inc. - BASF SE (Badische Anilin- und Soda-Fabrik) - Bayer AG - E. I. du Pont de Nemours and Company - Glanbia Plc - Herbalife, Ltd. - Koninklijke DSM N.V. - NBTY, Inc. - Nu Skin Enterprises, Inc. For more information visit http://www.researchandmarkets.com/research/ln...bal_market
HLF: 51.41 (+1.17), NUS: 41.62 (-0.19)
Baxalta: A Spin-Off That Could Be Revalued Up To 50% Higher
Mike Serebrennik - at Seeking Alpha - Mon Jul 06, 4:30PM CDT
BIIB: 388.23 (-11.06), NVO: 57.68 (+2.91), BAX: 37.61 (+0.59), PFE: 34.36 (+0.50), BXLT: 30.85 (+0.79)
The Weekender
Aviate - at Seeking Alpha - Sun Jul 05, 3:57AM CDT
Greece and Europe It is not over-exaggerating to say that all eyes are on Greece this weekend as the Greek people vote in the referendum. Where it was once seen as the most unlikely of outcomes, there now seems to be a real risk of Grexit,...
GREK: 11.26 (+0.95), TI: 13.19 (+0.48), RYAAY: 73.25 (+1.50), APOL: 14.01 (+0.43), BUD: 126.61 (+6.21), EU: 20.54 (-0.08), VOD: 36.46 (+1.07), PSO: 19.11 (+0.56)
What Is Beyond Vision-Loss Blockbuster For Regeneron?
at Investor's Business Daily - Wed Jul 01, 3:12PM CDT
As people get older, they are more prone to vision loss from age-related macular degeneration. The severe "wet" version of the condition is the leading cause of blindness in the U.S., afflicting millions of people over 55. It's caused by leaky,...
GILD: 113.74 (+0.38), AMGN: 154.10 (+2.79), SNY: 51.49 (+2.71), REGN: 526.01 (+16.98), CELG: 118.84 (+1.97)
Bayer Files Hemophilia A Drug Marketing Application in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 01, 2:50PM CDT
The HealthCare segment at Bayer (BAYRY) announced that the company has submitted a Marketing Authorization Application in Japan for BAY 81-8973.
BIIB: 388.23 (-11.06), EBS: 33.85 (+1.10), ACOR: 34.07 (+0.65)
Premarket Biotech Digest: Geron's Sharp Gain, Bayer Essure AEs, Juno Moves Higher
Kanak Kanti De - at Seeking Alpha - Wed Jul 01, 6:18AM CDT
JNJ: 99.53 (+1.13), GILD: 113.74 (+0.38), GERN: 4.22 (+0.13), ABBV: 69.23 (+1.26), CELG: 118.84 (+1.97)
